Sanofi Abandons Oral SERD Breast Cancer Drug As Pipeline Woes Mount
Menarini Remains In Front
Executive Summary
The Paris-headquartered company has thrown in the towel on its oral SERD, leaving Roche, Eli Lilly and AstraZeneca to pursue Menarini in the field.
You may also be interested in...
Sanofi Picks Venture Capitalist Ashrafian To Succeed Reed As R&D Head
The French drugmaker is banking on the wealth of expertise that Houman Ashrafian brings as both a scientist and biotech entrepreneur to drive forward its R&D efforts.
Boost For Oral SERDs As Menarini/Radius’ Orserdu Becomes First Approved For Breast Cancer
The firms’ Orserdu has won a US thumbs up for the treatment of ESR1-mutated advanced or metastatic breast cancer, marking a positive breakthrough for the challenging SERD drug class.
Five Clinical Trial Misses Of 2022
Drug makers have sought to branch into new frontiers of drug development in areas like cancers and neurology, but not all of them have been success stories. Here, Scrip looks at some of the more notable clinical trial misses of last year.